Journal of Neural Transmission

, Volume 123, Issue 2, pp 83–90

Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

DOI: 10.1007/s00702-014-1320-1

Cite this article as:
Grünblatt, E. & Riederer, P. J Neural Transm (2016) 123: 83. doi:10.1007/s00702-014-1320-1


Evidence suggests that aldehyde dehydrogenase (ALDH; E.C. gene, protein expression and activity are substantially decreased in the substantia nigra of patients with Parkinson’s disease (PD). This holds especially true for cytosolic ALDH1A1, while mitochondrial ALDH2 is increased in the putamen of PD. Similarly, in Alzheimer’s disease (AD) several studies in genetic, transcriptomic, protein and animal models suggest ALDH involvement in the neurodegeneration processes. Such data are in line with findings of increased toxic aldehydes, like for example malondialdehyde, nonenal, 3,4-dihydroxyphenylacetaldehyde and others. Genetic, transcriptomic and protein alterations may contribute to such data. Also in vitro and in vivo experimental work points to an important role of ALDH in the pathology of neurodegenerative disorders. Aims at investigating dysfunctions of aldehyde detoxification are suitable to define genetic/molecular targets for new therapeutic strategies balancing amine metabolism in devastating disorders like PD and probably also AD.


Aldehyde dehydrogenase Alzheimer’s disease Gene variation Parkinson’s disease Proteomic Transcription 

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  1. 1.University Clinics of Child and Adolescent Psychiatry, University of ZurichSchlierenSwitzerland
  2. 2.Neuroscience Center ZurichUniversity of Zurich and ETH ZurichZurichSwitzerland
  3. 3.University Hospital of Würzburg, Department of Psychiatry, Psychosomatics and PsychotherapyUniversity of WürzburgWürzburgGermany
  4. 4.Visiting ResearcherInstitute Cognitive Brain Sciences, NCGGObuJapan

Personalised recommendations